AR124048A1 - Inhibidores de la btk - Google Patents

Inhibidores de la btk

Info

Publication number
AR124048A1
AR124048A1 ARP210103131A ARP210103131A AR124048A1 AR 124048 A1 AR124048 A1 AR 124048A1 AR P210103131 A ARP210103131 A AR P210103131A AR P210103131 A ARP210103131 A AR P210103131A AR 124048 A1 AR124048 A1 AR 124048A1
Authority
AR
Argentina
Prior art keywords
alkyl
containing heterocycle
bicyclic
membered mono
independently
Prior art date
Application number
ARP210103131A
Other languages
English (en)
Inventor
Brian T Hopkins
Bin Ma
Isaac Marx
Jrgen Schulz
George Vandeveer
Robin Prince
Marta Nevalainen
Teyu Chen
Zain Yousaf
Martin Himmelbauer
Vatee Pattaropong
John Howard Jones
Edward Yin Lin
- Gonzalez Lopez De Turiso Felix Shiang
Thomas Purgett
Andrew George Capacci
Simone Sciabola
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of AR124048A1 publication Critical patent/AR124048A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable de este, donde: Het es fenilo, un heteroarilo de 5 - 6 miembros o un N-(alquilo C₁-C₃)piridonilo; X⁰ es N, X¹ es C, X² es N y X⁴ es N; X⁰ es CR⁰, X¹ es C, X² es N y X⁴ es N; X⁰ es CR⁰, X¹ es N, X² es C y X⁴ es N; X⁰ es CR⁰, X¹ es N, X² es C y X⁴ es CH; o X⁰ es CR⁰, X¹ es C, X² es N y X⁴ es CH; R⁰ es H, halo, metilo, halometilo, ciclopropilo, CN o fenilo; R¹ es H o alquilo C₁-C₃, alcoxi C₁-C₃, haloalquilo C₁-C₃ o un heterociclo que contiene oxígeno monocíclico de 4 - 7 miembros; R³ es H o halo; X³ está ausente, es CH₂, CH₂CH₂, O, O-CH₂*, O-CH₂CH₂*, NH, N(CH₃)-*, CH₂N(CH₃)-* o NH-CH₂*, donde “*” indica el punto de unión a R²; cuando X³ está ausente, es CH₂ o CH₂CH₂, R² es un heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido al núcleo bicíclico o a X³ a través de un átomo de nitrógeno del anillo (“unido en N”); cuando X³ es CH₂, CH₂CH₂, O, O-CH₂*, NH, N(CH₃)-*, CH₂N(CH₃)-* o NH-CH₂*, R² es un heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido a X³ a través de un átomo de carbono del anillo (“unido en C”), un heterociclo que contiene oxígeno mono o bicíclico de 4 - 7 miembros, un carbociclilo mono o bicíclico de 3 - 12 miembros, o un heteroarilo de 5 - 6 miembros; y cuando X³ es O-CH₂-CH₂*, R² está ausente, es un heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido a X³ a través de un átomo de carbono del anillo (“unido en C”) o un grupo alquilo C₁-C₃, siempre que, cuando R² esté ausente, X³ esté directamente conectado a R⁴; el heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido en N, el heterociclo que contiene oxígeno de 4 - 7 miembros, el carbociclo mono o bicíclico de 3 - 12 miembros, el heteroarilo de 5 - 6 miembros, y el grupo de alquilo C₁-C₃ representado por R² se sustituyen con un grupo representado por R⁴ y opcionalmente se sustituyen con uno a tres grupos representados por R¹⁰, siempre que, cuando el heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido en N contiene dos átomos de nitrógeno del anillo, el heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido en N, representado por R², se sustituye opcionalmente en N con un grupo representado por R⁵ y se sustituye opcionalmente de manera adicional con uno o dos grupos representados por R¹⁰; el heterociclo que contiene nitrógeno mono o bicíclico de 4 - 12 miembros unido en C se sustituye en N con un grupo representado por R⁵ y se sustituye opcionalmente de manera adicional con uno a tres grupos representados por R¹⁰; R⁴ es un compuesto del grupo de fórmulas (2); R⁵ es un compuesto del grupo de fórmulas (3); cada R⁶ es independientemente H, CN, alquilo C₁-C₃, haloalquilo C₁-C₃, N(Rᵃ)₂ o CH₂N(Rᵃ)₂, donde cada Rᵃ es independientemente H, alquilo C₁-C₃ o cicloalquilo C₃-C₆; cada R⁶’ es independientemente H, alquilo C₁-C₃, haloalquilo C₁-C₃ o cicloalquilo C₃-C₆; cada R⁷ es independientemente H, alquilo C₁-C₂, fluoroalquilo C₁-C₂ o cicloalquilo C₃-C₆; R⁸ es H o alquilo C₁-C₃; cada R¹⁰ es halo, alquilo C₁-C₃ o cicloalquilo C₃-C₆; R¹¹ es H o N(R¹²)₂; cada R¹² es independientemente H o alquilo C₁-C₃; R¹³ es CN o F; R¹⁴ es halo; cada n es independientemente 0 ó 1; cada p es independientemente 1 ó 2; y q es 1 ó 2.
ARP210103131A 2020-11-13 2021-11-12 Inhibidores de la btk AR124048A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063113515P 2020-11-13 2020-11-13

Publications (1)

Publication Number Publication Date
AR124048A1 true AR124048A1 (es) 2023-02-08

Family

ID=78828007

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103131A AR124048A1 (es) 2020-11-13 2021-11-12 Inhibidores de la btk

Country Status (14)

Country Link
US (1) US20240083900A1 (es)
EP (1) EP4244223A1 (es)
JP (1) JP2023549360A (es)
KR (1) KR20230119134A (es)
CN (1) CN116783199A (es)
AR (1) AR124048A1 (es)
AU (1) AU2021377891A1 (es)
BR (1) BR112023009116A2 (es)
CL (1) CL2023001367A1 (es)
CO (1) CO2023007677A2 (es)
MX (1) MX2023005626A (es)
TW (1) TW202233624A (es)
UY (1) UY39517A (es)
WO (1) WO2022104079A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086575A1 (en) * 2021-11-12 2023-05-19 Biogen Ma Inc. Btk inhibitors
WO2023220049A1 (en) * 2022-05-10 2023-11-16 Biogen Ma Inc. Crystalline polymorphs of n-methyl-n-((1s,3s)-3-methyl-3-((6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物
WO2024117205A1 (ja) * 2022-11-30 2024-06-06 北興化学工業株式会社 双環式ピリジン誘導体およびその塩、並びに、当該誘導体又はその塩を有効成分として含有することを特徴とする有害生物防除剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055645A1 (en) * 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
CA2918242C (en) * 2013-07-31 2022-06-21 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
EP3891149A4 (en) * 2018-12-07 2022-09-07 Sunshine Lake Pharma Co., Ltd. RET INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Also Published As

Publication number Publication date
EP4244223A1 (en) 2023-09-20
UY39517A (es) 2022-06-30
US20240083900A1 (en) 2024-03-14
WO2022104079A1 (en) 2022-05-19
CO2023007677A2 (es) 2023-09-08
CN116783199A (zh) 2023-09-19
KR20230119134A (ko) 2023-08-16
MX2023005626A (es) 2023-07-31
JP2023549360A (ja) 2023-11-24
BR112023009116A2 (pt) 2023-10-03
CL2023001367A1 (es) 2024-01-05
TW202233624A (zh) 2022-09-01
AU2021377891A1 (en) 2023-07-06
AU2021377891A9 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
AR124048A1 (es) Inhibidores de la btk
AR110922A1 (es) Compuestos inhibidores del vih
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR111419A1 (es) Compuestos fusionados de indazol piridona como antivirales
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR108875A1 (es) COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AR093364A1 (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
AR058769A1 (es) Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen.
AR113929A1 (es) Compuestos heterocíclicos
AR100059A1 (es) Compuestos útiles como inmunomoduladores
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
AR103252A1 (es) Compuestos de quinazolina
AR100975A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR117616A1 (es) Compuestos anti-vih
AR065824A1 (es) Sulfonilbenzamidas sustituidas con heterociclos bloqueantes de los canales de sodio,formulaciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del dolor y particularmente del dolor cronico.
AR093580A1 (es) Inhibidores bmi-1 de pirimidina sustituidos
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR093579A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR089120A1 (es) Compuestos herbicidas
AR089550A1 (es) Compuestos quimicos
AR107840A1 (es) INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g